PT -期刊文章AU -沃克,伊恩·f . AU - Shi Oumin AU -希克斯,约瑟夫·p . AU - Elsey海伦AU -魏,迪克AU - Lan,小林AU -孟知益盟——Falzon丹尼斯盟——Migliori Giovanni Battista盟——Perez-Guzman卡洛斯AU -巴尔加斯,马里奥•h . AU - Garcia-Garcia卢尔德AU - Sifuentes Osornio,穆盟——庞塞德利昂,Alfredo AU - van der Walt, Martie AU - Newell，詹姆斯·n·TI -分析的追踪损失4099耐多药肺结核患者援助- 10.1183/13993003.00353 -2018 DP - 2019年7月01 TA -欧洲呼吸杂志》第六PG - 1800353 - 54 IP - 1 4099 - //www.qdcxjkg.com/content/54/1/1800353.short 4100 - //www.qdcxjkg.com/content/54/1/1800353.full所以欧元Respir J2019 7月01日;54 AB -随访失败(LFU)≥连续2个月导致结核病规划报告的耐多药结核病(MDR-TB)治疗成功水平较低。我们研究了耐多药结核病治疗当月发生LFU的时间，并确定了与LFU相关的患者水平风险因素。我们分析了单个耐多药结核病患者数据集(来自22个国家的4099名患者)。我们使用Kaplan-Meier生存曲线来绘制到LFU的时间，并使用Cox比例风险模型来探索潜在危险因素与LFU的关系。约六分之一(n=702)的患者被记录为LFU。中位(四分位数范围)发生LFU的时间为7(3-11)个月。大部分LFU发生在治疗初期(75%发生在前11个月)。与LFU相关的主要危险因素为:年龄36-50岁(HR 1.3, 95% CI 1.0-1.6; p=0.04) compared with age 0–25 years, being HIV positive (HR 1.8, 95% CI 1.2–2.7; p<0.01) compared with HIV negative, on an individualised treatment regimen (HR 0.7, 95% CI 0.6–1.0; p=0.03) compared with a standardised regimen and a recorded serious adverse event (HR 0.5, 95% CI 0.4–0.6; p<0.01) compared with no serious adverse event.Both patient- and regimen-related factors were associated with LFU, which may guide interventions to improve treatment adherence, particularly in the first 11 months.Globally, 75% of loss to follow-up occurs in the first 11 months of MDR-TB treatment. Highest risk is HIV positive, age 36–50 years and standardised regimen. http://bit.ly/2GwKcS1